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Abstract
Aims and objectives This systematic literature review
aims to assess the reliability, validity and responsiveness of
three widely used generic preference-based measures of
health-related quality of life (HRQL), i.e., EQ-5D, Health
Utility Index 3 (HUI3) and SF-6D in patients with skin
conditions.
Methods A systematic search was conducted to identify
studies reporting health state utility values obtained using
EQ-5D, SF-6D, or HUI3 alongside other HRQL measures
or clinical indices for patients with skin conditions. Data on
test-retest analysis for reliability, known group differences
or correlation and regression analyses for validity, and
change over time or responsiveness indices analysis were
extracted and reviewed.
Results A total of 16 papers reporting EQ-5D utilities in
people with skin conditions were included in the final
review. No papers for SF-6D and HUI3 were found. Evi-
dence of reliability was not found for any of these measures.
The majority of studies included in the review (12 out of 16)
examined patients with plaque psoriasis or psoriatic arthritis
and the remaining four studies examined patients with either
acne, hidradenitis suppurativa, hand eczema, or venous leg
ulcers. The findings were generally positive in terms of
performance of EQ-5D. Six studies showed that EQ-5D was
able to reflect differences between severity groups and only
one reported differences that were not statistically signifi-
cant. Four studies found that EQ-5D detected differences
between patients and the general population, and differences
were statistically different for three of them. Further, mod-
erate-to-strong correlation coefficients were found between
EQ-5D and other skin-specific HRQL measures in four
studies. Eight studies showed that EQ-5D was able to detect
change in HRQL appropriately over time and the changes
were statistically significant in seven studies.
Conclusions Overall, the validity and responsiveness of
the EQ-5D was found to be good in people with skin dis-
eases, especially plaque psoriasis or psoriatic arthritis. No
evidence on SF-6D and HUI3 was available to enable any
judgments to be made on their performance.
Keywords EQ-5D  Validity  Responsiveness 
Skin conditions
JEL Classification I120
Introduction
In the UK and elsewhere, a common practice in economic
evaluation of health technologies is to use cost-utility
analysis, where results are presented as an incremental cost
per quality adjusted life year (QALY) gained [1, 2]. The
QALY method provides a way of measuring the benefits of
health care interventions by combining both improvements
in health-related quality of life (HRQL) and extension of
life years into a single index. The QALY is estimated by
weighting survival with a value reflecting the HRQL
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experienced during the time period, where the HRQL value
is estimated to reflect the ‘utility’ of the health state.
Health state utility values are commonly estimated using
one of the generic preference-based measures (GPBMs) of
HRQL. Examples of the most commonly used GPBMs
include the EQ-5D [3, 4], SF-6D [5] and the Health Utilities
Index (HUI) [6]. GPBMs typically use a multi-dimensional,
multi-level descriptive system of health combined with a
utility value set that can be applied to each unique health state
described by the system. The health state utility values
associated with GPBMs are usually obtained from general
population-based valuation studies using techniques such as
time trade-off or standard gamble. These values are on a
scale where a weight of 0 corresponds to a health state ‘dead’
(as well as, potentially, to health states considered as bad as
being dead) and a weight of 1 corresponds to full health,
which meets the requirement for QALY calculation. The
combination of the generic descriptive system and value sets
of GPBMs enables users to reflect the value people place on
different health states make comparisons of health outcomes
across different conditions [7].
The descriptive systems of the commonly used GPBMs
differ in terms of their dimensions. EQ-5D has five dimen-
sions of health including mobility, self-care, usual activities,
pain/discomfort, and depression/anxiety. The original ver-
sion of EQ-5D has three levels of severity in each dimension;
and a version with five levels of severity has recently been
developed [8]. The three-level version describes 243 health
states. We refer to the three level EQ-5D though out this
paper. Derived from the SF-36 and SF-12 health question-
naires, the SF-6D has six dimensions of health including
physical functioning, role limitation, social functioning,
bodily pain, mental health, and vitality, and each dimension
has four to six severity levels. The health state of any patient
who completes the SF-36 or the SF-12 can be classified
according to the SF-6D system. The health classification
systemof SF-6Ddescribes a total of 18,000 health states. The
HUI3 has eight dimensions of health including vision,
hearing, speech, ambulation, dexterity, emotion, cognition,
and pain, and each dimension has five or six severity levels.
The health classification system of HUI3 describes almost a
million unique health states. The HUI3 can be seen as a
‘within-the-skin’ measure of health because it contains
sensory dimensions such as vision, speech and hearing, and
concerns health or health problems, whereas the EQ-5D and
SF-6D focus more on how health impacts on functioning in
life although both SF-6D and EQ-5D also have symptom-
related dimensions (e.g., pain and discomfort).
Apart from the different descriptive systems, the sample
populations, valuation, and extrapolation techniques used to
arrive at the value sets of the measures also differ. Several
value sets are available for the EQ-5D to reflect the different
values of different countries such as UK, France, Germany,
Netherlands, Denmark, Spain, Japan, and USA. The UK
value set of EQ-5D has been the most widely used and it
was obtained from valuations provided by 3,395 members
of the general population using the time trade-off valuation
method. The UK value set of SF-6D was obtained from
valuations provided by 611 members of the general popu-
lation using the standard gamble valuation method and
similar values sets have been obtained in Japan, Hong
Kong, Portugal, and Brazil. Similarly, tariffs of values for
each health state of HUI3 is available estimated from
Canadian and UK samples. The original Canadian value set
was obtained from valuations provided by 504 members of
the general population using the visual analogue scale
(VAS) and standard gamble (SG) valuation methods.
Given the different descriptive systems and valuation
methods, there has been evidence showing that health state
utility values obtained from the three GPBMs can be dif-
ferent [9–11]. GPBMs, especially EQ-5D, have attracted
criticism for perceived failure to capture important aspects
of health and insensitivity to change in specific health
conditions [12–16]. There might be specific circumstances
in which the EQ-5D or other GPBMs are not appropriate to
use. Therefore, it is important to assess the performance of
EQ-5D and other GPBMs for a wide range of conditions
and/or treatments. This type of research can provide evi-
dence on whether these measures are appropriate for those
specific conditions and aid the judgment of whether or when
alternative measures should be considered. The examina-
tion of the validity and responsiveness of GPBMs is fraught
with conceptual and empirical problems due to the lack of a
gold standard measure. However, conventional psycho-
metric tests of construct validity and responsiveness can
inform judgments about the appropriateness of measures of
health in a comprehensive and transparent way [17].
A review of the evidence on the psychometric perfor-
mance of GPBMs in skin disorders has not been previously
undertaken. On the other hand, skin disorders like psoriasis
and atopic eczema have a profound influence on patients’
lives. The painful or itching symptoms of skin conditions
may affect patients’ social lives, their daily work, and their
personal relationships [18, 19]. The aim of this study was
to systematically review the published literature to assess
the reliability, validity, and responsiveness of three key
generic measures of health-related quality of life (EQ-5D,
HUI3, and SF-6D) in people with skin disorders.
Methods
Search strategy and data identification
We conducted a systematic search of published papers
reporting EQ-5D, HUI3, and SF-6D in patients with skin
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diseases using a search strategy developed following con-
sultation with experts in information resources, clinicians,
and health economists. The search strategy focused on
keywords, including ‘skin impairment/disorder/disease’,
‘euroqol/EQ-5D’, ‘hui3’, and ‘sf6d’, all with alternative
spellings. Specific terms of skin diseases were obtained
from ICD-10; examples, included ‘impetigo’ ‘furunculo-
sis’, and ‘cutaneous abscess’. The search strategy used for
MEDLINE is presented in the ‘‘Appendix’’.
We searched the following electronic databases: BIOSIS
(1969–2010); CINAHL (1982–2010); Cochrane Library
comprising the Cochrane Database of Systematic Reviews
(CDSR), Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Methodology Register, NHS
Economic Evaluations Database (NHS EED) (1991–2010);
EMBASE (1980–2010); MEDLINE (in process and non-
indexed–2010); PsychNFO (1806–2010); and Web of
Science (1900–2010). We also conducted a search of the
EuroQol Group database for possible relevant studies for
EQ-5D [20]. Similar searches were not conducted for HUI3
and SF-6D as comparable databases are not available.
We used the following inclusion criteria to identify
relevant papers, where:
1. the study population had any skin diseases; and
2. the study reported at least one of the three GPBMs
(EQ-5D, SF-6D, or HUI3); and
3. the study reported another measure of quality of life
(generic or condition-specific), a measure of clinical
severity, or direct valuation of health.
This implies that papers are excluded if:
1. the study only reported EQ- Visual Analogue Scale
(VAS) scores; or
2. the study only used vignettes or own health state
valuations, not one of the three generic measures; or
3. the study did not report another measure of quality of
life (generic or condition-specific) or a measure of
clinical severity, or direct valuation of health, along-
side the three measures of interests; lastly papers were
excluded where they were written in languages other
than English.
Data extraction
We extracted data from the included studies using a form
developed in Microsoft Excel, which covered general
characteristics of the study and participants, instruments
used in the study, methods and relevant results provided in
the included study for an assessment of reliability, con-
struct validity, and responsiveness. Studies did not have to
be specifically designed to assess reliability, responsive-
ness or validity provided sufficient data were presented to
allow us to make an assessment. For example, studies were
included if they reported results of analyses of change over
time using the GPBM and a comparison measure (to
indicate a change had occurred) or if they reported analyses
of the GPBM according to subgroups defined by a com-
parison measure of health (known group validity). Our
analyses are based on data provided in the included papers
and we did not carry out these analyses by ourselves. Data
extraction was undertaken by one member of the research
team and summarized using items presented in Table 1.
Data analysis
Assessment of quality and relevance
The quality of a study was assessed by examining the risk
of bias from the methods of patient recruitment, and noting
any missing data reported either study drop-outs or
incomplete questionnaires. The purpose of assessing study
Table 1 Data extracted from included papers
General information
of the study
Author name(s), publication year
Country where study was conducted
Type of skin diseases
Disease/treatment stage
Treatment (if any)
Study design (e.g., randomized control trial,
cross-sectional study, etc.)
Characteristics of
participants
Number of participants
Age (mean and range)
Gender (percentage of males)
Ethnicity
Missing data (respondent drop-out/non-
completion), including reasons for non-
completion if given
Measures and
valuations reported
General measures used
Tariff or source of value sets
Mean values reported (standard deviation
range)
Direct valuations used
Condition-specific HRQL measures used
Clinical measures used
Qualitative questions asked
Missing data (within measure completion)
Reliability Methods used
Results reported
Validity Methods used (e.g., known group,
correlation coefficients, regressions)
Results reported
Responsiveness Methods used (e.g., significance of change
over time, effect size).
Results reported
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quality was not to exclude relevant studies, but to highlight
any concerns about quality when findings were being
interpreted. Most important was to assess the relevance of
the study in terms of the patient population and evidence to
judging the psychometric performance of the generic
measures. Studies were not required to be specifically
designed to assess validity, responsiveness or reliability
provided that they reported data in a sufficient detail to
allow an assessment of these.
Assessment of reliability
A measure can claim reliability if it reproduces stable
results when measurements are repeated on an unchanged
population. Reliability can be assessed by test-retesting and
reporting the correlation or difference between estimates.
Where GPBM values did not change over time and other
measures of health demonstrated no change in health over
the same period, the results were interpreted as evidence of
the reliability of instruments.
Assessment of construct validity
Validity is defined as how well an instrument measures
what it was intended to measure. Validity can be assessed
by comparing an instrument to an established gold stan-
dard; however a gold standard does not exist in health
utility measurement. Therefore it is necessary to assess the
validity of GPBMs using measures having evidence of
construct validity, which establishes if patterns in scores
confirm constructs or hypotheses about expected patterns.
We assessed the construct validity of the GPBMs using
the ‘known group’ method that compares (qualitatively or
statistically using t test orANOVA) the values obtained from
the GPBMs between groups of patients who are expected to
differ according to clinical severity or other measures of
HRQL. Known groups can also be defined using a case–
control analysis where comparison is between population of
patients and the general public without the condition; or
defined on the basis of other aspects such as age, gender, etc.
We also examined convergent validity, which is a type
of construct validity. Convergent validity is defined as the
extent to which one measure correlates with another mea-
sure of the same or similar concept. In this review, we
examined the extent to which EQ-5D, SF-6D or the HUI3
correlate with other measures of HRQL or clinical severity.
Correlation was defined as ‘low’ if the correlation coeffi-
cient was less than 0.3, ‘moderate’ if between 0.3 and 0.5,
and ‘strong’ if greater than 0.5. Further, we interpreted
regression estimates of the relationship between GPBMs
and other measures as another indication of convergence
focusing on whether measures were significant predictors
of the others.
Assessment of responsiveness
Responsiveness assesses the ability of an instrument to
measure a change in health over time. As with construct
validity, there is no gold standard measure for change. We
assessed the responsiveness of the GPBMs by comparing
change in GPBM values over a period of time in which
health status is expected to change (for example before and
after an intervention) with the change demonstrated by
another measure of health. We considered there to be
strong evidence of responsiveness if the GPBM showed
statistically significant change in health (e.g., t test), which
was demonstrated by other measures or clinical indicators.
Where there was the expected trend of change (e.g.,
improvement or decline) but the change was not statisti-
cally significant then this was interpreted as weak sup-
portive evidence.
We also compared responsiveness indices (e.g., effect
size or standard response mean) of health-related utility
with those of other measures when they were reported.
Effect size is the mean change score of a measure between
two time points divided by the standard deviation of the
score at baseline whereas standardized response mean is
similarly the mean change score divided by the standard
deviation of the change score [21].
Results
Search results
The bibliographic search identified a total of 161 records
from the electronic databases and two additional records
from the EuroQol Group website database. We excluded
122 records after reviewing titles and abstracts. Forty-one
papers were reviewed in full, a further 25 papers were
excluded and 16 papers were included in the final review
(see Fig. 1).
Quality assessment—skin conditions
The included studies reported three types of study designs.
Eleven studies were RCTs (including one study only
reported the baseline data), four studies were cross-sec-
tional, and one was an uncontrolled before-and-after study.
The majority of studies provided clear inclusion and
exclusion criteria for recruitment of patients; however
inclusion and exclusion criteria were not clear for two
studies [22, 23]. Ten studies reported that between 70 and
97 % respondents completed the planned follow-up; data
were not reported on completion for six papers. The
completion rates of individual questionnaires (i.e., item
response of a questionnaire with no missing data) were
930 Y. Yang et al.
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generally high (above 90 %). No study was excluded after
the assessment of quality.
Study design, patients’ characteristics, and measures
used in studies
The main characteristics of the 16 papers included in this
review are shown in Table 2. Studies were conducted in
various European and American countries, with several
multi-national studies. All but five studies recruited
patients with psoriasis, the remaining studies recruited
patients with acne, eczema, hidradenitis suppurativa, or
venous leg ulcers. All studies included adult patients (mean
age around 43 years). In these studies, male respondents
accounted for 24–71 % of the samples. Sample size ranged
from 32 to 27,994 but most studies had a sample size of
between 100 and 200. EQ-5D utility values were reported
in all but two studies and the mean values ranged from 0.5
to 0.82.
The measures used in the 16 studies are summarized in
the last column of Table 2. Of the three GPBMs of interest,
only EQ-5D data were found and included in the review.
No studies reported data from SF-6D and HUI3. The
majority of studies used the UK tariff to obtain the EQ-5D
utility values but for several studies it was not clear which
tariff was used [23–25]. Fourteen studies reported VAS
scores of patients’ own perceived health in addition to the
EQ-5D index values. Various clinical indices were reported
to indicate severity of skin problems, including Psoriasis
Area Severity Index (PASI) in eight studies, Nail Psoriasis
Severity Index (NAPSI) in one study, and acne grade in
one study. Several generic measures [e.g., SF-36, Health
Assessment Questionnaire Disability Index (HAQ-DI),
Health Assessment Questionnaire (HAQ)], skin-specific
HRQL measures [e.g., Dermatology Life Quality Index
(DLQI)], or symptom specific HRQL measures [e.g.,
Hospital Anxiety and Depression Scale (HADS); Depres-
sion Inventory] were reported in these studies.
Reliability
No study reported data on reliability of the three GPBMs.
Construct validity and responsiveness
Thirteen studies among patients with skin problems pro-
vided sufficient evidence to allow assessment of known
group validity and convergent validity of EQ-5D. Among
them, nine studies included patients with psoriasis or pso-
riatic arthritis, one study each included patients with acne,
hidradenitis suppurativa, hand eczema, and venous leg
ulcers.
Eleven studies among people with skin problems pro-
vided evidence to allow assessment of responsiveness of
EQ-5D. Among them, eight studies included patients with
psoriasis or psoriatic arthritis, one study included patients
with acne, and one study focused on venous leg ulcers. Ten
studies examined changes of scores over time or after
treatment, and two provided details of effect size or stan-
dard response mean estimation. One study checked the
Number of potentially relevant records 
identified electronically 
163 
Number of citations screened 
163 
Number of citations excluded based on 
review of titles and abstracts 
122 
Number of full text articles assessed 
41 
Number of full text articles excluded 
                       25 
Number of papers included in review 
16 
Fig. 1 Flow diagram showing
selection of studies for skin
review
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correlation between change scores of health measures with
changes in clinical measures.
We summarize findings of construct validity and
responsiveness of EQ-5D on various skin conditions below.
Plaque psoriasis and psoriatic arthritis
Known group analysis
Seven studies allowed known group analysis for EQ-5D
among people with psoriasis or psoriatic arthritis. Among
them, three studies showed that EQ-5D was able to dis-
criminate severity groups significantly. Christopher et al.
[25] reported that EQ-5D values of people with psoriatic
arthritis (PsA) were statistically lower than psoriatic
arthritis (0.56 vs. 0.82, p\ 0.001). Daude´n [26] reported
that EQ-5D values differed between the two treatment
groups (p\ 0.05) and this was confirmed by EQ-VAS and
DLQI but not HADS-Depression and HADS-Anxiety
subscale, or SF-36 vitality and the satisfaction survey.
Another study conducted by Luger [27] indicated that EQ-
5D was able to discriminate (p\ 0.1) between patients
with or without joint pain, and patients with or without nail
psoriasis, which was consistent with a series of measures
including EQ-VAS, PASI, DLQI, SF-36 vitality, and
HADS.
Three case–control studies confirmed that EQ-5D can
differentiate between people with psoriasis and the general
population [23, 28, 29]. Another study by Brodszky et al.
[30] found that the standardized mean difference between
groups measured by EQ-5D were lower than that produced
by the Psoriatic Arthritis Quality of Life Instrument
(PsAQoL) and the HAQ. However, the groups were
defined according to admission to hospital, receipt of a
disable pension, use of devices or requiring help from
others for everyday activities; whilst these may be sug-
gestive of disease severity they are likely to be confounded
by other factors, for example, disabled pension maybe
indicative of age or better overall income than those who
receive a different kind of pension.
Convergent validity
Four studies provided evidence of convergent validity for
EQ-5D among patients with psoriasis and psoriatic arthri-
tis. Three studies showed moderate or strong correlation
between EQ-5D and other generic or skin-specific mea-
sures. Brodsky et al. [30] reported a strong correlation
coefficient of over 0.5 between EQ-5D and HAQ, Psoriatic
Arthritis Quality of Life scale (PsAQoL), the pain VAS,
the patient global VAS and the Bath Ankylosing Spondy-
litis Disease Activity Index (BASDAI). Shikiar et al. [31]
found that EQ-5D was moderately to strongly correlated
with EQ-VAS, DLQI, PASI, Physician Global Assessment
of psoriasis (PGA), and SF-36 domains. Similarly, Weiss
et al. [29] demonstrated that EQ-5D was strongly corre-
lated with Patient’s Satisfaction With Life Scale (SWLS)
scores (correlation coefficients 0.46, p\ 0.05) and eight
domains of SF-36 (correlation coefficients ranged from
0.62 to 0.78, p\ 0.001). Through a regression analysis,
Bansback et al. [24] suggested that the HAQ disability
index was a significant predictor of EQ-5D (coefficient
-0.31, p\ 0.05).
Responsiveness
All nine studies among patients with psoriasis or psoriatic
arthritis confirmed that EQ-5D was responsive to change in
health over time in this condition. Daude´n et al. [26]
reported that being consistent with the EQ-VAS, DLQI,
HADS-Anxiety scale, and the SF-36 vitality dimension,
EQ-5D values improved significantly (p\ 0.05) and clin-
ically meaningfully from baseline for both treatment
groups. Luger et al. demonstrated that EQ-5D values
improved significantly (change of 0.17, by 29 %) alongside
EQ-VAS (change of 12.87, by 23 %), DLQI (change of
8.86, by 61 %), the SF-36 vitality dimension (change of
5.6, by 11 %), HADS-Depression (change of 1.9, by
29 %), HADS-Anxiety (change of 2.27, by 28 %) among
patients with joint pain. However, for patients with nail
psoriasis, EQ-5D did not detect a significant improvement,
whereas a significant improvement was found by other
measures [27]. Reich et al. [28] reported that at both fol-
low-up time points, the group who received active treat-
ment achieved significant improvement compared to
placebo measured using EQ-5D, EQ-VAS, FACT-Fatigue,
and DLQI (both total and domain scores). Similarly,
Revicki et al. [32] reported that statistically significant
improvement (p\ 0.001) was detected for treatment
groups by EQ-5D, DIQI, and Psoriasis PASI, and the dif-
ference between treatment and placebo groups was sig-
nificant by all measures. Shikiar et al. [33] confirmed that
two treatment groups improved significantly greater than
placebo measured using EQ-5D (p\ 0.01), EQ-VAS
(p\ 0.01), and most SF-36 domains (p\ 0.05), as well as
DLQI. Another study [31] showed that EQ-5D and DLQI,
PASI, PGA, EQ-VAS, and most SF-36 domains detected
significant differences between responders and non-
responders and DLQI was the most responsive with an
effect size of 0.4 and EQ-5D had an effect size of 0.12,
which was comparable to EQ-VAS and SF-36 domains.
Weissi et al. [34] reported that after 2 weeks of therapy,
scores improved significantly as shown by EQ-5D (by
11.5 %, p\ 0.05), EQ-VAS (by 8.2 %, p\ 0.001), PASI
(by 26.2, p\ 0.05), total body surface (by 20.4 %,
p\ 0.001) and another version of the PASI (i.e., SAPASI)
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(by 26.2 %, p\ 0.05). Finally, Van de Kerkhof [23]
showed that significant improvement was detected by EQ-
VAS, Psoriasis Disability Index, and the pain/discomfort
and anxiety/depression dimensions of EQ-5D although no
statistical tests were reported.
Acne
Known group analysis
In a case–control study, Klassen et al. [22] found that
patients with acne reported higher proportions of problems
for most EQ-5D dimensions than the general population,
especially pain and anxiety.
Convergent validity
No study reported convergent validity in patients with
acne.
Responsiveness
Klassen et al. [22] reported that after treatment the pro-
portion of participants reporting a moderate problem on
EQ-5D dimensions dropped greatly after treatment. EQ-5D
utility values showed a significant change after treatment,
which was consistent with SF-36 physical component
summary score, and DLQI. A moderate effect size
(0.44–0.53) for EQ-5D was reported whereas it was 0.98
for the DLQI, 0.3–0.5 for the SF-36 summary score, and
1.57 for the acne grades.
Hidradenitis suppurativa
Known group analysis
For patients with hidradenitis suppurativa, Matusiak et al.
[35] found that significant differences (p\ 0.01) according
to severity groups defined by Hurley’s classification groups
were suggested by EQ-5D, EQ-VAS, DLQI, and the Beck
Depression Inventory-Short Form.
Convergent validity
Moderate correlation (0.28 to 0.39, p\ 0.05) was reported
between EQ-5D with DLQI and EQ-5D with Functional
Assessment of Cancer Therapy-Fatigue module (FACT-F)
[35].
Responsiveness
No study reported responsiveness in patients with hidrad-
enitis suppurativa.
Hand eczema
Known group analysis
Among patients with hand eczema, Moberg et al. [36]
suggested that EQ-5D and EQ-VAS significantly
(p\ 0.05) differ between groups defined according to
whether they have hand eczema, as well as age and gender
subgroups. The proportion of reporting any problems on
the EQ-5D dimensions were also found for more groups
with more severe disease but no statistical tests were
reported.
Convergent validity
Moberg et al. [36] reported a strong correlation between
EQ-5D and EQ-VAS among hand eczema patients.
Responsiveness
No study reported responsiveness in patients with hand
eczema.
Venous leg ulcers
Known group analysis
In patients with venous leg ulcers, Walters et al. [37]
reported small effect sizes (less than 0.2) for the EQ-5D,
EQ-VAS, SF-36, and Frenchay Activities Index (FAI) for
patients grouped on the basis of their initial leg ulcer size,
current ulcer duration, maximum ulcer duration, and age.
On the other hand, the differences were statistically sig-
nificant (p\ 0.05) for the EQ-5D, EQ-VAS, FAI, and five
subscales of SF-36 when groups were defined by whether
they had none, moderate, or severe problems with mobility.
Convergent validity
Walters et al. [37] reported that EQ-5D achieved moderate-
to-high correlation coefficients with SF-36 domains, the
FAI, and the McGill Short Form Pain Questionnaire (SF-
MPQ).
Responsiveness
Walters et al. [37] reported mixed results in a study of
compression healing of venous leg ulcers in different set-
tings. When grouped according to how well patients’ leg
ulcers had healed at 3 months, a deterioration of health
status over time was shown by the EQ-5D. Results from the
SF-36 confirmed this, but conflicted with results from the
VAS and the Short-form McGill Pain Questionnaire.
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Discussion and conclusions
This study aimed to systematically review and assess the
validity, reliability and responsiveness of three GPBMs,
namely EQ-5D, HUI3, and SF-6D in patients with skin
diseases. There were no papers on the HUI3 and SF-6D,
which met our inclusion criteria. The 16 studies included in
the review provide useful information to assess the per-
formance of EQ-5D skin disorders (see Table 3 for details).
The findings were generally positive in terms of per-
formance of EQ-5D. However, given the limited evidence
for skin conditions apart from the plaque psoriasis and
psoriatic arthritis for which most evidence was identified,
this positive conclusion may not be generalizable to all skin
conditions.
In the studies, EQ-5D was assessed in terms of ability to
discriminate between groups or detect changes over time,
and the convergence with other measures was taken as the
evidence to support positive performance of EQ-5D. It is
important to consider whether the measures of health that
are being used for comparison are valid themselves. In
addition, consideration must be given to the appropriate-
ness of the clinical measure and the groups defined by it,
and exogenous factors that may influence HRQL. For
example, many studies included in our review used PASI,
which is an accepted measure of psoriasis severity com-
monly used in studies of psoriasis and has been used as a
measure of severity in development of clinical guidelines,
but it does not measure HRQL. It is only an indicator for
better or worse health.
It should be noted that the usefulness of the comparisons
between HRQL measures can be limited by sample size,
particularly as studies are usually not powered to detect
differences according to preference-based measures. For
instance, groups defined solely by the presence of a bio-
marker may have no impact on HRQL. Also, if patients
have a number of co-morbidities, then these may have a
greater impact on HRQL than the condition of interest.
We acknowledged that there was heterogeneity in the
studies reviewed, in terms of study design, patient popu-
lations, and other HRQL measures used. However, in
Table 3, each study was treated equally as a piece of evi-
dence to assess the overall performance of health utility
measure. This issue should be taken into account when
interpreting the findings. Although there was a systematic
search of literature across various databases, a limitation if
the study is that the data extraction was undertaken mainly
by one reviewer, with a sample of excluded papers checked
Table 3 Overall performances of EQ-5D in skin conditions
Conditions Known group
(severity)
Known group
(case–control)
Known group
(other)
Correlation Responsiveness
Cons Sig Cons Sig Cons Sig Cons Sig
Bansback et al. [24] Psoriatic arthritis 4
Brodszky et al. [30] Psoriatic arthritis 4 4 Strong
Christophers et al. [25] Plaque psoriasis and
Psoriatic arthritis
4 4
Daude´n et al. [26] Plaque psoriasis 4 4 4 4
Van de Kerkhof [23] Plaque psoriasis 4 N/R 4 N/R
Luger et al. [27] Plaque psoriasis 4 4 4 4
Reich et al. [28] Plaque psoriasis 4 4 4 4
Revicki et al. [32] Plaque psoriasis 4 4
Shikiar et al. [31] Psoriasis Moderate
to strong
4 4
Shikiar et al. [33] Psoriasis 4 4
Weiss et al. [29] Psoriasis
Weiss et al. [34] Psoriasis 4 4 Moderate (sig) 4 4
Klassen et al. [22] Acne 4 4 4 4
Matusiak et al. [35] Hidradenitis
suppurativa
4 4 Moderate
Moberg et al. [36] Hand eczema 4 4 4 4
Walters et al. [37] Venous leg ulcers 4 N/R 4 N/R ? N/R
Empty cells indicate ‘no information is available’
Cons consistent evidence, Sig Statistically significant
4 = Yes; ? = Mixed evidence; 8 = No; N/R = no report
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by a second reviewer. Also, the review limited papers to
those written in the English language, which might have
excluded papers written in other languages. Further, the
current review focused only on the three-level version of
EQ-5D. Following increasing interest in and usage of the
newly developed five-level EQ-5D measure, a similar
review may be needed to examine how it performs in skin
diseases. As demonstrated by a recent study [39], the five-
level EQ-5D dimensions were good predictors of the pso-
riasis-specific DLQI and the SAPASI scores and it could
differentiate severity groups defined by both DLQI and
SAPASI scores. The study however also highlighted that
including two additional dimensions specific to psoriasis
increased the explanatory power of EQ-5D-5L to predict
the DLQI and SAPASI scores, and this was also confirmed
in the valuation study. The implications are that EQ-5D
may perform satisfactorily for psoriasis, but bolt-on pso-
riasis-specific dimensions could potentially improve
validity and responsiveness further.
It is surprising that no studies were found to provide
sufficient evidence to assess performance of HUI3 and SF-
6D in skin conditions. Also, no papers on reliability of any
of the measures, including EQ-5D, were identified, which
is a concern.
This is the first time information on the validity and
responsiveness of GPBMs has been comprehensively
reported and analyzed in skin disorders. Similar reviews
using the same methodology have been undertaken for
vision [14], mental health conditions [13, 16], hearing [38],
and cancer [38]. We have established that EQ-5D is a
responsive and valid measure of GBPM for use in patients
with psoriasis and psoriatic arthritis. There was less evi-
dence in patients with other skin conditions, but the limited
evidence was generally supportive of EQ-5D. No evidence
was found to assess the psychometric properties of HUI3
and SF-6D in patients with skin conditions, and no evi-
dence on reliability was identified for any of the measures.
This is a review of existing empirical studies on validity
and responsiveness of GPBMs in patients with skin disor-
ders. Empirical studies are needed to assess performance of
HUI3 and SF-6D in patients with skin conditions, and to
expand knowledge of EQ-5D in patients with other skin
conditions apart from psoriasis and psoriatic arthritis.
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Appendix: Search strategy used in MEDLINE
for the skin review
(Database: Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations and Ovid MEDLINE(R) h1950 to
Presenti).
1 [euroqol or euro qol or eq5d or eq 5d or eq-5d or
(euro adj qol) or (eur adj qual) or (eq adj 5d)].mp.
(2,151)
2 (hui3 or hui 3 or health utilities index mark 3 or health
utilities mark three or hui III or huiIII).mp. (231)
3 (sf6D or sf 6D or short form 6D or shortform 6D or sf
six D or sfsixD or shortform six D or short form sixD
or sf-6d or 6d or 6-d or 6 dimension).mp. (4,538)
4 1 or 2 or 3 (6,722)
5 Staphylococcal scalded skin syndrome.mp. or staph-
ylococcal scalded skin syndrome/(414)
6 Impetigo.mp. or Impetigo/(1,457)
7 boil.mp. or Furunculosis/(1,278)
8 furunculosis.mp. (1,165)
9 Cutaneous abscess.mp. (66)
10 Cellulitis/or Cellulitis.mp. (8,369)
11 Acute lymphadenitis.mp. (30)
12 Pilonidal cyst.mp. (116)
13 Pyoderma/or Pyoderma.mp. (3,928)
14 Erythrasma.mp. or Erythrasma/(175)
15 Pemphigus/or Pemphigus.mp. (7,253)
16 Pemphigoid.mp. or Pemphigoid, Bullous/(4,942)
17 Dermatosis.mp. or Skin Diseases/(46,511)
18 Acantholysis/or Acantholytic disorder.mp. (660)
19 Dermatitis/or Dermatitis.mp. (59,308)
20 Eczema/or eczema.mp. (13,886)
21 prurigo.mp. or Prurigo/(1,207)
22 Pruritus.mp. or Pruritus/(13,152)
23 Lichen simplex chronicus.mp. or Neurodermatitis/
(1,396)
24 Dyshidrosis.mp. (104)
25 Erythema intertrigo.mp. (2)
26 Pityriasis alba.mp. (79)
27 Papulosquamous.mp. (861)
28 Psoriasis.mp. or Psoriasis/(27,853)
29 Acrodermatitis/or Acrodermatitis continua.mp.
(1,813)
30 Pustulosis.mp. (1,302)
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31 Urticaria/or Urticaria.mp. (12,733)
32 erythema.mp. or Erythema/(2,5199)
33 Sunburn.mp. or Sunburn/(2,693)
34 Dermatitis, Phototoxic/(528)
35 Dermatitis, Photoallergic/or Photoallergic.mp. (700)
36 Solar urticaria.mp. (228)
37 Actinic keratosis.mp. or Keratosis, Actinic/(944)
38 Actinic reticuloid.mp. (139)
39 Cutis rhomboidalis nuchae.mp. (12)
40 Poikiloderma of Civatte.mp. (36)
41 Cutis laxa senilis.mp. (0)
42 Actinic granuloma.mp. (49)
43 Acne.mp. (11,465)
44 Rosacea.mp. or Rosacea/(2,084)
45 Vitiligo.mp. or Vitiligo/(4,053)
46 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or
25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or
44 or 45 (212,215)
47 4 and 46 (60)
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